Circulating cell-free DNA as predictor of pathological complete response in locally advanced rectal cancer patients undergoing preoperative chemoradiotherapy

Sung, 2021, Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, 209, 10.3322/caac.21660 Heald, 1982, The mesorectum in rectal cancer surgery—the clue to pelvic recurrence?, Br J Surg, 69, 613, 10.1002/bjs.1800691019 Paun, 2010, Postoperative complications following surgery for rectal cancer, Ann Surg, 251, 807, 10.1097/SLA.0b013e3181dae4ed Hartley, 2005, Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials, Br J Radiol, 78, 934, 10.1259/bjr/86650067 Appelt, 2015, High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study, Lancet Oncol, 16, 919, 10.1016/S1470-2045(15)00120-5 Habr-Gama, 2006, Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy, Colorectal Dis, 8, 21, 10.1111/j.1463-1318.2006.01066.x van der Valk, 2018, Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study, Lancet, 391, 2537, 10.1016/S0140-6736(18)31078-X López-Campos, 2020, Watch and wait approach in rectal cancer: current controversies and future directions, World J Gastroenterol, 26, 4218, 10.3748/wjg.v26.i29.4218 Boysen, 2018, Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer, Clin Chim Acta, 487, 107, 10.1016/j.cca.2018.09.029 Schou, 2018, Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer, Ann Oncol, 29, 610, 10.1093/annonc/mdx778 Lefèvre, 2020, Measurement of circulating free DNA in squamous cell carcinoma of the anus and relation to risk factors and recurrence, Radiother Oncol, 150, 211, 10.1016/j.radonc.2020.06.045 Sun, 2014, The role of plasma cell-free DNA detection in predicting preoperative chemoradiotherapy response in rectal cancer patients, Oncol Rep, 31, 1466, 10.3892/or.2013.2949 Zitt, 2008, Circulating cell-free DNA in plasma of locally advanced rectal cancer patients undergoing preoperative chemoradiation: a potential diagnostic tool for therapy monitoring, Dis Markers, 25, 159, 10.1155/2008/598071 Agostini, 2011, Circulating cell-free DNA: A promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy, Ann Surg Oncol, 18, 2461, 10.1245/s10434-011-1638-y Boysen, 2017, Cell-free DNA levels and correlation to stage and outcome following treatment of locally advanced rectal cancer, Tumor Biol, 39, 10.1177/1010428317730976 Goldshtein, 2009, A rapid direct fluorescent assay for cell-free DNA quantification in biological fluids, Ann Clin Biochem, 46, 488, 10.1258/acb.2009.009002 McShane, 2005, Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK), JNCI J Natl Cancer Inst, 97, 1180, 10.1093/jnci/dji237 Index for rating diagnostic tests – Youden – 1950 – Cancer – Wiley Online Library. Accessed September 6, 2021. https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/1097-0142(1950)3:1%3C32::AID-CNCR2820030106%3E3.0.CO;2-3. Guo Z-W, Yang X, Xiao W, et al. Noninvasive in vivo Assessment of the Effectiveness of Cancer Therapy Using Promoter Profiling of Circulating Cell-Free DNA. SSRN Electron J. 2020. doi:10.2139/SSRN.3514720. Massihnia, 2019, Liquid biopsy for rectal cancer: a systematic review, Cancer Treat Rev, 79, 10.1016/j.ctrv.2019.101893 F S, G B, D C, et al. Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. Br J Cancer. 2017;117(10):1478-1485. doi:10.1038/BJC.2017.320. Glynne-Jones R, Wallace M, Livingstone JIL, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a “wait and see” policy justified? doi:10.1007/s10350-007-9080-8. Nygaard AD, Holdgaard PC, Spindler K-LG, Pallisgaard N, Jakobsen A. The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC. 2014. doi:10.1038/bjc.2013.705. Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv22-iv40. doi:10.1093/annonc/mdx224.